Articles that tag ARKG but are mainly about other companies.
The ETF's significant investment in CRISPR Therapeutics through Cathie Wood's recent purchases reflects confidence in genomic revolution themes and CRISPR's potential as a core holding in the fund's strategy.
Up 64% year-to-date in 2026 and nearly doubled over the past year, significantly outperforming most other Ark ETFs. Strong market for biotechs and gene-editing stocks has fueled substantial gains.
The ETF holds $92 million in CRISPR Therapeutics, further demonstrating Ark's confidence in gene-editing and genomic innovation as a long-term investment theme.
Similar to Ark Innovation ETF, this is executing standard portfolio rebalancing by trimming a large position to reallocate capital.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology